We renew our call for establishing a registry for Depo-Provera users for research and so women could be notified if future concerns arise. Knowing to whom it is given, under what circumstances and with what outcomes may lead to a deeper understanding of how to assess social risks, and identify ways clients in difficult situations can be helped to address the roots of the problems they are facing. With Depo-Provera approved, the hard work lies ahead. For every 100 women taking Depo-Provera at correct intervals for one year, less than one will become pregnant. Studies suggest Depo-Provera is protective against endometrial cancer and may protect against ovarian and cervical cancer and pelvic inflammatory disease.
More research is needed.
Most women using Depo-Provera experience menstrual irregularities such as irregular bleeding or spotting, and for some, heavy bleeding. This may make early detection of pregnancy difficult, while other women may worry unnecessarily that they might be pregnant. Fetal development may be affected by exposure to Depo-Provera. Menstrual irregularities may also mask the onset of menopause. The delay in return to fertility averages 3-6 months, but may be up to 18 months or more for a small number of women.